[Advances in the study of anti-atherosclerosis drugs].
Several new drug targets of anti-atherosclerosis, emerging in the recent years, such as PPAR agonists, cholesteryl ester transfer protein (CETP) inhibitors, infusion of apolipoprotein A-I (apoA-I), liver X receptor (LXR) activators and phospholipid transfer protein (PLTP) inhibitors etc were reviewed.
Guo
Chang-Bin
CB
Institute of Pharmacology & Toxicology, Academy of Military Medical Sciences, Beijing 100850, China.
Li
Song
S
D016632:Apolipoprotein A-I / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D001565:Benzoates / Q000737:chemistry / Q000627:therapeutic use*; D001596:Benzylamines / Q000737:chemistry / Q000627:therapeutic use*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000819:agonists / Q000378:metabolism; D006801:Humans; D000071518:Liver X Receptors; D015394:Molecular Structure; D057093:Orphan Nuclear Receptors; D010078:Oxazines / Q000737:chemistry / Q000627:therapeutic use*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000378:metabolism; D010666:Phenylpropionates / Q000737:chemistry / Q000627:therapeutic use*; D011804:Quinolines / Q000737:chemistry / Q000627:therapeutic use*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000378:metabolism
D016632:Apolipoprotein A-I; D001565:Benzoates; D001596:Benzylamines; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D004268:DNA-Binding Proteins; C473027:GW 3965; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D010078:Oxazines; D047492:Peroxisome Proliferator-Activated Receptors; D010666:Phenylpropionates; D011804:Quinolines; D018160:Receptors, Cytoplasmic and Nuclear; C483909:torcetrapib; C432703:ragaglitazar